Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBIT: 2020-2024

Historic EBIT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$128.4 million.

  • Arcutis Biotherapeutics' EBIT rose 121.82% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.2 million, marking a year-over-year increase of 78.98%. This contributed to the annual value of -$128.4 million for FY2024, which is 46.75% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' EBIT stood at -$128.4 million, which was up 46.75% from -$241.1 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year EBIT high stood at -$128.4 million for FY2024, and its period low was -$301.6 million during FY2022.
  • In the last 3 years, Arcutis Biotherapeutics' EBIT had a median value of -$241.1 million in 2023 and averaged -$223.7 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' EBIT crashed by 51.14% in 2021, and later surged by 46.75% in 2024.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' EBIT stood at -$136.6 million in 2020, then tumbled by 51.14% to -$206.5 million in 2021, then plummeted by 46.05% to -$301.6 million in 2022, then increased by 20.07% to -$241.1 million in 2023, then surged by 46.75% to -$128.4 million in 2024.